In this interview, Christopher D'Angelo, MD, University of Nebraska Medical Center, Omaha, NE, comments on the optimal management of TP53-mutated mantle cell lymphoma (MCL), noting that standard chemotherapy approaches are ineffective and that novel therapies are a superior option for this patient population. Dr D'Angelo emphasizes the importance of sequencing to identify mutations and guide subsequent treatment decisions. In most patients, Dr D'Angelo favors the BOVen trial regimen (NCT03824483) if a suitable clinical trial is not available. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.